FASENRA®
FASENRA® (Benralizumab) is an immunosuppressive drug that is used as an add-on maintenance therapy for patients with severe Eosinophilic Asthma.
FASENRA® is manufactured by AstraZeneca.
Administration and Dosage:
Administration of FASENRA® follows an induction regimen of 3 subcutaneous injections every 4 weeks followed by a maintenance injection, once every 8 weeks.
Common Side Effects:
The more common side effects of FASENRA® include allergic (hypersensitivity) reactions, including anaphylaxis.
More information:
Please read the full Prescribing Information and Instructions for Use for FASENRA® and discuss any questions you have with your doctor.
Indication:
FASENRA® is indicated to treat:
Add-on Maintenance for Severe Eosinophilic Asthma
Contact Us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!
Check our Privacy Practice